Naphthyridine-Substituted Pyridazine Compounds for Selective M4 Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction, such as schizophrenia, face challenges due to the lack of potent and selective activators of the M4 muscarinic acetylcholine receptor, leading to adverse effects from non-specific activation of peripheral receptors.
Innovation Solution
Development of naphthyridine-substituted pyridazine compounds that act as positive allosteric modulators of the M4 muscarinic acetylcholine receptor, binding to an allosteric site distinct from the orthosteric site to selectively enhance receptor activity without triggering peripheral side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AChE inhibitors are used to increase acetylcholine levels, then therapeutic efficacy for cognitive deficits is improved, but gastrointestinal side effects and hepatotoxicity worsen
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for specific mAChR subtypes (M1, M3, or M5) rather than non-selectively inhibiting AChE. This subtype-selective activation allows therapeutic effects in target brain regions while minimizing peripheral side effects, as different mAChR subtypes are distributed differently throughout the body
Solution Approach 2:
The patent changes the pharmacological parameter from non-specific AChE inhibition to specific mAChR subtype activation. By modifying the mechanism of action to target specific receptor subtypes rather than broadly increasing acetylcholine levels, the therapy achieves efficacy while reducing off-target adverse effects
2Reliability
If mAChR agonists are used to activate muscarinic receptors, then cognitive function is improved, but peripheral side effects worsen due to non-selective activation
Solution Approach 1:
The patent applies local quality by creating agonists with selective affinity for specific mAChR subtypes (M1, M3, or M5) that are predominantly expressed in the central nervous system. This selective activation achieves cognitive benefits while minimizing activation of peripheral mAChRs that mediate adverse effects such as bradycardia and gastrointestinal distress
3Adaptability or versatility
If selective M4 agonists are developed to target psychotic disorders, then therapeutic specificity is improved, but compound selectivity worsens due to difficulty in achieving high M4 selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with selective affinity for specific mAChR subtypes (M1, M3, or M5) rather than attempting to develop M4-selective agonists. This subtype-selective approach achieves therapeutic specificity for cognitive and psychiatric disorders while avoiding the difficulties encountered in developing highly selective M4 agonists
Data Source
AI summary
5,6,7,8-Tetrahydro-1,6-naphthyridines substituted in the 6-position with pyrimido[1,2-b]pyridazin-4-one are positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.